133 related articles for article (PubMed ID: 32097722)
1. Development of a nanoparticle that releases nucleic acids in response to a mitochondrial environment.
Yamada Y; Fukuda Y; Sasaki D; Maruyama M; Harashima H
Mitochondrion; 2020 May; 52():67-74. PubMed ID: 32097722
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Mitochondrial Genome Via a MITO-Porter : Evaluation of mtDNA and mtRNA Levels and Mitochondrial Function.
Yamada Y; Harashima H
Methods Mol Biol; 2021; 2275():227-245. PubMed ID: 34118041
[TBL] [Abstract][Full Text] [Related]
3. Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease.
Muratovska A; Lightowlers RN; Taylor RW; Turnbull DM; Smith RA; Wilce JA; Martin SW; Murphy MP
Nucleic Acids Res; 2001 May; 29(9):1852-63. PubMed ID: 11328868
[TBL] [Abstract][Full Text] [Related]
4. Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.
Kawamura E; Hibino M; Harashima H; Yamada Y
Mitochondrion; 2019 Nov; 49():178-188. PubMed ID: 31472283
[TBL] [Abstract][Full Text] [Related]
5. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
Yamada Y; Harashima H
Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
[TBL] [Abstract][Full Text] [Related]
6. Targeted nucleic acid delivery to mitochondria.
Vaidya B; Mishra N; Dube D; Tiwari S; Vyas SP
Curr Gene Ther; 2009 Dec; 9(6):475-86. PubMed ID: 20021331
[TBL] [Abstract][Full Text] [Related]
7. Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter.
Kawamura E; Maruyama M; Abe J; Sudo A; Takeda A; Takada S; Yokota T; Kinugawa S; Harashima H; Yamada Y
Mol Ther Nucleic Acids; 2020 Jun; 20():687-698. PubMed ID: 32388194
[TBL] [Abstract][Full Text] [Related]
8. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].
Furukawa R; Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(12):1389-98. PubMed ID: 23208046
[TBL] [Abstract][Full Text] [Related]
9. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
Yamada Y; Harashima H
Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
[TBL] [Abstract][Full Text] [Related]
10. RNA Delivery to Mitochondria.
Yamada Y; Harashima H
Handb Exp Pharmacol; 2024; 284():329-339. PubMed ID: 37017791
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.
Yamada Y; Munechika R; Kawamura E; Sakurai Y; Sato Y; Harashima H
J Pharm Sci; 2017 Sep; 106(9):2428-2437. PubMed ID: 28478130
[TBL] [Abstract][Full Text] [Related]
12. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
Yamada Y; Furukawa R; Yasuzaki Y; Harashima H
Mol Ther; 2011 Aug; 19(8):1449-56. PubMed ID: 21694702
[TBL] [Abstract][Full Text] [Related]
13. Arginine-based poly(ester amide) nanoparticle platform: From structure-property relationship to nucleic acid delivery.
You X; Gu Z; Huang J; Kang Y; Chu CC; Wu J
Acta Biomater; 2018 Jul; 74():180-191. PubMed ID: 29803783
[TBL] [Abstract][Full Text] [Related]
14. Treatment of human cells derived from MERRF syndrome by peptide-mediated mitochondrial delivery.
Chang JC; Liu KH; Chuang CS; Su HL; Wei YH; Kuo SJ; Liu CS
Cytotherapy; 2013 Dec; 15(12):1580-96. PubMed ID: 24199594
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.
Furukawa R; Yamada Y; Kawamura E; Harashima H
Biomaterials; 2015 Jul; 57():107-15. PubMed ID: 25913255
[TBL] [Abstract][Full Text] [Related]
16. Mitophagy induced by nanoparticle-peptide conjugates enabling an alternative intracellular trafficking route.
Zhang Z; Zhou L; Zhou Y; Liu J; Xing X; Zhong J; Xu G; Kang Z; Liu J
Biomaterials; 2015 Oct; 65():56-65. PubMed ID: 26142776
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter.
Kawamura E; Yamada Y; Harashima H
Mitochondrion; 2013 Nov; 13(6):610-4. PubMed ID: 24012978
[TBL] [Abstract][Full Text] [Related]
18. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
Yamada Y
Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.
Ishikawa T; Somiya K; Munechika R; Harashima H; Yamada Y
J Control Release; 2018 Mar; 274():109-117. PubMed ID: 29408532
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
Yasuzaki Y; Yamada Y; Harashima H
Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
